Community Bank N.A. Has $289,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Community Bank N.A. lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,680 shares of the medical equipment provider’s stock after selling 160 shares during the period. Community Bank N.A.’s holdings in Zimmer Biomet were worth $289,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth about $28,000. Bangor Savings Bank acquired a new stake in Zimmer Biomet during the third quarter worth approximately $31,000. Family Firm Inc. bought a new stake in shares of Zimmer Biomet during the second quarter worth approximately $33,000. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of Zimmer Biomet in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $110.50 on Tuesday. The stock has a market cap of $22.00 billion, a PE ratio of 21.01, a P/E/G ratio of 2.06 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The business’s 50-day moving average price is $107.29 and its two-hundred day moving average price is $109.30.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the prior year, the company earned $1.65 EPS. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ZBH. Canaccord Genuity Group reduced their price target on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 10th. TD Cowen dropped their target price on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Wells Fargo & Company upped their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. dropped their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research note on Monday, September 16th. Finally, Oppenheimer cut their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.